Hisamitsu Pharmaceutical Co., Inc.
HTSUF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.22 | -0.48 | 0.11 | 2.45 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 31.46 | 0.00 | 21.99 | 29.78 |
| Quality | ||||
| ROIC | 1.22% | 0.81% | 1.70% | 1.11% |
| Gross Margin | 61.59% | 61.40% | 55.43% | 61.40% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 4.65% | 4.93% | 6.73% | 6.18% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -15.59 | 0.00 | -15.25 | -17.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.62 | 0.53 | 0.89 | 0.58 |
| Cash Conversion Cycle | 155.40 | 227.24 | 131.62 | 196.70 |